60 Degrees Pharmaceuticals (SXTP)
Develops and markets tafenoquine medicines for malaria prevention and vector-borne diseases.
Something off on this page? Send us feedback.
Markets ARAKODA in the United States and KODATEF in Australia and New Zealand for adult malaria prevention, while developing tafenoquine and castanospermine-based programs for vector-borne diseases. Revenue combines distributor product sales with cost-reimbursement research work, and operations rely on contractors, collaborators, distributors and external supply.
Markets ARAKODA in the United States and KODATEF in Australia and New Zealand, branded tafenoquine products for preventing malaria in adults. The medicine is sold through pharmaceutical resellers, a third-party logistics provider, distributors and pharmacy benefit managers; ARAKODA requires quantitative G6PD testing before prescription. FDA approval is limited to malaria prevention; tafenoquine is not approved for babesiosis. Research revenue chiefly supports new packaging and supply-chain validation, alongside clinical-trial supply and Australian incentives.
Develops tafenoquine for babesiosis through a controlled hospitalized-patient study and programs for relapsing and chronic disease, while pursuing veterinary tafenoquine and castanospermine-based compounds. A virtually managed, single-segment operation has no manufacturing capacity and relies on contractors, research collaborators, distributors and external supply, with all tafenoquine inventory acquired through one vendor relationship.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.0M · Total debt $151.2K · Total assets $4.3M · Shareholders' equity $2.6M
- Revenue
- $207.9K
- Operating income
- −$2.3M
- Net income
- −$2.3M
No dividends on record.
| Institutions8 holders · as of Mar 31, 2026 | 5.53% | 194.3K shares | |
| Insiders4 holders · as of Jun 15, 2026 | 0.95% | 33.3K shares | |
| Strategic holders2 holders · as of Jul 29, 2026 | 21.00% | 738.6K shares | |
| Otherremainder | 72.52% | 2.55M shares |
3.52M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (3.52M in the company's Sep 3, 2026 report, 806.6K elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Knight Therapeutics Inc.Strategic10 percent owner | 18.73% | 658,629 | 13Gfiled Jul 29, 2026 ↗ |
Lind Global Fund III LPInstitution | 5.45% | 191,571 | 13Gfiled Aug 5, 2026 ↗ |
Kathmere Capital Management, LLCInstitution | 4.11% | 144,683 | 13Fas of Mar 31, 2026 |
Orca Capital AGStrategic | 2.27% | 80,000 | 13Gfiled Jul 17, 2025 ↗ |
UBS Group AGInstitution | 0.89% | 31,410 | 13Fas of Mar 31, 2026 |
| See all 23 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 12, 2026 | Geoffrey S. Dow | director, officer: President and CEO | +7,350 | $1.38 |
| Dec 15, 2025 | Geoffrey S. Dow | director, officer: President and CEO | +9,670 | $0.8024 |
| Dec 10, 2025 | Geoffrey S. Dow | director, officer: President and CEO | +9,350 | $0.9504 |
| Dec 11, 2025 | Geoffrey S. Dow | director, officer: President and CEO | +3,613 | $0.9184 |
